All In Biotech

Drug Trial Radar · NCT05649722

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

Last checked: Nov 19, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

31

Actual

Start

May 11, 2023

Primary completion

Apr 1, 2026

Study completion Apr 1, 2026

Sponsor

Lead sponsor
Insmed IncorporatedIndustry
Sponsor type
Industry
First posted
Dec 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-211 (NCT05176951) and other lead-in studies of TPIP in participants with PH-ILD.

Conditions

  • Pulmonary Hypertension
  • Interstitial Lung Disease

Interventions

  • Treprostinil Palmitil Inhalation PowderDrug

    Oral inhalation using a capsule-based dry powder inhaler device.

  • PlaceboDrug

    Oral placebo inhalation using a capsule-based dry powder inhaler device.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experienced a Treatment Emergent Adverse Event (TEAE)Time frame: Up to approximately 25 months

Locations

22 sites in 7 countries. Site status is shown where the registry gives one.

  • ARG003

    Autonomus City of Buenos Aires, Buenos Aires, Argentina

  • ARG001

    Rosario, Santa Fe Province, Argentina

  • AUS005

    Macquarie Park, New South Wales, Australia

  • BEL002

    Liège, Belgium

  • GER002

    Berlin, Germany

  • GER012

    Berlin, Germany

  • GER006

    Heidelberg, Baden-Wurttemberg, Germany

  • GER004

    München, Bavaria, Germany

  • GER010

    Giessen, Hesse, Germany

  • GER003

    Essen, North Rhine-Westphalia, Germany

  • GER001

    Dresden, Saxony, Germany

  • ITA003

    Naples, Italy

  • ITA004

    Milan, Lombardy, Italy

  • ITA002

    Monza, Lombardy, Italy

  • ITA001

    Palermo, Sicily, Italy

  • ESP005

    Barcelona, Spain

  • ESP010

    Barcelona, Spain

  • ESP003

    Palma, Balearic Islands, Spain

  • ESP009

    Santiago de Compostela, Galicia, Spain

  • ESP007

    Oviedo, Principality of Asturias, Spain

  • GBR003

    Clydebank, Glasgow, United Kingdom

  • GBR001

    Sheffield, South Yorkshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.